MA5-16124

antibody from Invitrogen Antibodies

Targeting: SREBF1 bHLHd1, SREBP-1c, SREBP1, SREBP1a

Provider product page for MA5-16124

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [24]
Comments [0]
Validations
Western blot [1]
Other assay [2]

Submit

Product number: MA5-16124 - Provider product page
Provider: Invitrogen Antibodies
Product name: SREBP1 Monoclonal Antibody (2A4)
Antibody type: Monoclonal
Antigen: Other
Description: In Western blot, a band can be seen at 125 kDa (precursor) and additional bands may be seen at 60-70 kDa (cleaved).
Antibody clone number: 2A4
Concentration: 1 mg/mL

SREBF1 protein structure - MA5-16124 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Reduction of liver steatosis by TNFR1 inhibition in NAFLD mice. a NAFLD mice treated with anti-TNFR1-Ab for 8 weeks revealed decreased liver steatosis, detected by Oil Red O staining, compared to mice treated with control-Ab (scale bars: 50 um). Representative results of anti-TNFR1-Ab-treated ( n = 7) and control-Ab-treated ( n = 6) mice are shown. b Liver steatosis, as semi-quantitatively assessed by pathologist, was significantly decreased in NAFLD mice treated with anti-TNFR1-Ab ( n = 7) compared to control-Ab ( n = 6) treatment. c Compared to control-Ab administration ( n = 6), TNFR1-Ab treatment ( n = 7) resulted in a significant decrease of liver triglyceride content. d Western blot analysis of liver extracts from two representative mice treated with either anti-TNFR1-Ab or control-Ab. Mice treated with TNFR1-Ab revealed ameliorated mTOR activation (p-mTOR), as well as decreased expression and cleavage-mediated activation of transcription factor SREBP1 compared to control-Ab-treated mice. Accordingly, expression of SREBP1-regulated target genes of lipogenesis, i.e., fatty acid synthase (FAS) and stearoyl-CoA desaturase-1 (SCD1) was decreased in liver tissues from TNFR1-Ab-treated compared to control-Ab-treated mice. All images were derived from the same blots; the vertical lines indicate juxtaposition of lanes non-adjacent within the same blot. e Densitometric analyses revealed a significantly higher ratio of phosphorylated compared to non-phosphorylated version

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Prmt5 regulates fatty acid metabolic pathways through interacting with SREBP1a. a) Heatmap of top 25 significant changed TAGs from eWAT of WT (Prmt5 flox/flox ) and Prmt5 AKO mice (upper) and list of TAGs that were decrease by >2-fold in Prmt5 AKO compared to WT (Prmt5 flox/flox ) eWAT (lower), n = 5 pairs male mice of 6-month-old. b) Concentration of FFA, cholesterol, HDL, LDL, and TAG from the serum of WT (Prmt5 flox/flox ) and Prmt5 AKO mice, n = 4 pairs male mice of 6-month-old. c) Heatmap of top 25 significant changed TAGs from WT (Prmt5 flox/flox ) and Prmt5 AKO mice (upper) and list of TAGs that were decreased by >1.6-fold in Prmt5 AKO compared to WT (Prmt5 flox/flox ) eWAT (lower), after 12-week of HFD, n = 4 pairs of male mice. d) Concentration of FFA, cholesterol, HDL, LDL, and TAG from the serum of WT (Prmt5 flox/flox ) and Prmt5 AKO mice, n = 3 pairs male mice after 12-week HFD feeding. e) Fold change of Free Fatty Acids (FFA) in eWAT of WT (Prmt5 flox/flox ) and Prmt5 AKO mice. f) Ratio of 18:1/16:0 FFA indicating de novo lipogenesis. e,f) n = 5 pairs of 6-month-old male mice. g,h) Expression of g) adipogenic and h) lipogenic genes in eWAT from WT (Prmt5 flox/flox ) and Prmt5 AKO mice, n = 3 pairs of male mice at 6-month-old. i) Representative Western blots showing relative protein levels of PPAR gamma , ATGL, CEBP alpha , FABP4, and beta -Tubulin from eWAT of male WT (Prmt5 flox/flox ) and Prmt5 AKO mice after 12-week of HFD. j) Heatmap from RNA-sequenc